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Polymeric micelles that can deliver drug to intended sites of the eye have attracted
much scientific attention recently. The aim here is to review the aqueous-based formula-
tion of drug loaded polymeric micelles that hold significant promise for ophthalmic drug
delivery. These innovative nanosystems can provide the biopharmaceutical advantages of
higher permeation and enhancement of residence time at ocular surface for better drug
absorption through ocular barriers. Mucoadhesive properties of biopolymers forming mi-
celle enhance their contact time and minimize their elimination from the absorbing sur-
face, consequently increasing the bioavailability of the drug. Their physicochemical
characteristics are also important with respect to the industrial production and patient
compliance. Drug loaded polymeric micelles can be fabricated by simple and cost effec-
tive techniques with improved physical stability which fulfils the requirements for indus-
trial acceptance. Innovative polymeric micelle formulations allow their easy application
in the form of eye drops without blurring of vision and discomfort, thus achieving pa-
tient compliance requirements.
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Introduction
Ocular drug delivery is faced with significant
challenges due to dynamic, tissue and ocular-blood
barriers. In terms of drug delivery, the eye can be
considered to have four target sites: (i) the pre-ocu-
lar structures of the front of the eye (e.g. conjunc-
tiva, eyelids); (ii) the cornea; (iii) the anterior and
posterior chamber and associated tissues; and (iv)
posterior eye segment (e.g. retina, vitreous cavity).1
The administration of the drug to the front of
the eye is typical for the anterior segment therapies
(pre-ocular, corneal and anterior/posterior regions).
The tear dynamics creates a lively environment of
the front of the eye. The solution drainage rate con-
stant from the pre-corneal area is 1.45 min–1. The
rate of drug loss from the eye surface can be 500 to
700 times greater than the rate of drug absorption
into the anterior chamber, and consequently, less
than 5% of the applied dose reaches the intraocular
tissues.2,3 The rate of aqueous humor turnover is es-
timated to be 1.0% to 1.5% of the anterior chamber
volume per minute (i.e. total turnover 1.5–2 h). The
drug can reach the anterior chamber via trans-cor-
neal permeation from tears or via blood-aqueous
barrier from the systemic circulation. Distribution
volume of drugs in anterior chamber is in the range
of 150–3000 l. The drug clearance rates generally
are in range of 1–30 l min–1.2
Cornea is the major route of anterior drug
absorption. There are three corneal layers, namely
epithelium, stroma, and endothelium, and all of
them have a distinct role in trans-corneal drug per-
meability. The corneal epithelium is the major lim-
iting barrier in trans-corneal drug absorption. The
drug permeation across corneal epithelium is deter-
mined by passive diffusion, facilitated diffusion or
active transport. The passive permeation of
lipophilic drugs occurs via the transcellular path-
way, while the passive permeation of hydrophilic
drugs occurs via the tight junctions regulated
paracellular pathway. In general, drug permeation
across the corneal epithelium is 10–7–10–5 cm s–1. In
contrast to the epithelium, the hydrophilic stroma
presents a barrier to lipophilic substances, which
move along the transcellular route through the epi-
thelium. Finally, the endothelium is a leaky
monolayer that is easily permeated and participates
only marginally in the corneal barrier function.
Clinically used drugs are generally small and
lipophilic. Thus, the trans-corneal route of drug
absorption is currently dominating, although the
trans-corneal rate constants are relatively low
(1–5 × 10–3 min–1).4–7
The surface area of human conjunctiva is about
17-fold larger than human corneal surface area.
Conjunctival epithelium is composed of 2–3 cell
layers with tight junctions that present the barrier to
the passive permeation of hydrophilic molecules
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found at the apical surface of these cells. However,
human conjunctiva is between two- and 30-fold
more permeable to drugs than the cornea.8 The
conjunctival epithelium has 2 times larger
paracellular pores and 16 times higher paracellular
pore density than the cornea. The total paracellular
space in the conjunctiva was estimated to be 230
times greater than that in the cornea.9
The drug absorption through the conjunc-
tival-scleral pathway has gained increasing atten-
tion recently, due to the permeability of conjunctiva
to the hydrophilic and large molecules. This path-
way can be of high importance for the intraocular
delivery of new biotech-drugs such as proteins,
peptides and nucleic acid based therapeutics.5
Trans-scleral route may be suitable for delivery of
biotech-drugs to the retina and vitreous, if appropri-
ate delivery systems are developed.10 Permeability
through the sclera is considered to be comparable to
that of the corneal stroma, i.e. hydrophilic drugs
may diffuse through the scleral matrix pores more
easily than lipophilic drugs. The permeability of
drug molecules across the sclera is inversely pro-
portional to the molecular radius as well as
lipophilicity of drug molecules.7 The charge of the
drug molecule also affects its permeability across
the sclera. Positively charged molecules exhibit
poor permeability presumably due to their binding
to the negatively charged scleral matrix. 8,11
The blood-ocular barriers limit the effec-
tiveness of the drug delivery to the posterior seg-
ment from the systemic blood circulation. The
blood-aqueous barrier is located in the anterior seg-
ment of the eye and limits the entry of drugs from
the blood into the aqueous humor. The blood-retinal
barrier (BRB) restricts the transport of drugs from
blood into the retina i.e. inward movement follow-
ing periocular or systemic drug administration and
outward movement after intravitreal drug adminis-
tration.7,12 The drug permeation from the vitreous
humor across the retina is restricted by retinal lay-
ered structures.13 The common method for posterior
drug delivery is ocular injection. Intravitreal injec-
tion can provide adequate drug concentrations in
the posterior segment of the eye, but with the high-
est risk of ocular complications. The risk is lower
with periocular (e.g. sub-tenon) drug administra-
tion. Owing to the invasive nature of the injection,
it is important to design drug formulations to main-
tain the therapeutic drug concentration over pro-
longed periods and minimize the number of injec-
tions.10,14–16
Nano-ophthalmology, the application of nano-
medicine to ocular diagnosis and treatment, has the
potential to transform clinical ophthalmology by
enhancing the efficacy of eye therapy for a wide
spectrum of innovative formulation of either new or
existing ocular drugs. Ocular drug delivery nano-
systems have been widely explored to bypass or
transport the drug across various ocular barriers, as
well as to sustain drug levels at the target site of the
eye. Design of the innovative ocular drug delivery
nanosystems and development of non-invasive
techniques for their ocular applications may consid-
erably improve the field of ocular drug delivery.
Advances in the nano-based ocular dosage forms
are expected to provide new tools for the treatment
of the various anterior and posterior eye segment
diseases. A number of nanocarriers intended to by-
pass and/or transport the drugs to the anterior and
posterior segment of the eye have been investi-
gated, namely: nanoparticles,2,17–19 nanosuspen-
sions,20,21 solid lipid nanoparticles,22 nanostructured
lipid carriers,23 liposomes,24 niosomes,25 cubosomes,26
microemulsions,27,28 dendrimers.29 Yet, the potential
of polymeric micelles intended for the ophthalmic
application is less explored in comparison to their
application in cancer therapy.30,31 To date, the great-
est contributions in this area have been made by
Gupta et al.,32 by the Kataoka group,33 Liaw
group,34,35 and our group.36,37 Several of these ex-
amples are listed in Table 1.
Ocular drug delivery nanosystems can be pre-
pared as aqueous-based ophthalmic colloidal disper-
sions, which allow their application in the form of
eye drops or eye injections. Eye drops are preferred
ocular form used by patients, due to their ease in us-
age and low interference with vision. However, in-
corporation of drugs into specially designed
nanocarriers would lead to the improved bio-
pharmaceutical properties (e.g. prolonged retention
at the site of application, modified drug release).
These systems offer additional industrial advantages,
especially relatively simple and inexpensive sterile
production i.e. the possibility of sterile filtration due
to the small particle size (usually less than 100
nm).17,48–50 However, the majority of these systems
are not on the pharmaceutical market due to unre-
solved problems related to the cost, bulk manufactur-
ing (e.g., the ability to scale up the production), pa-
tient compliance (e.g., vision interference, discom-
fort) and approval by regulatory authorities.
The innovative nano-based ocular dosage
forms should maintain the advantages of the con-
ventional ocular therapeutics (i.e., patient compli-
ance and industrial acceptance) while enhancing
biopharmaceutical properties (i.e., enhanced ocular
bioavailability).17,48,51 The challenge is to provide a
system with improved ocular drug bioavailability
and prolonged duration of activity, but still with a
minimum risk of ocular complications. These sys-
tems can potentially increase patient compliance by
reducing the dosing frequency and invasive treat-
ment.
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CsA physically entrapped into polymeric
micelles; CsA-loading: 4.9 mg ml–1
dh = 54 nm CsA-loaded micelles overcome corneal barriers de-
livering therapeutics CsA concentration in ocular tis-






DEX physically entrapped into mixed
micelle hydrophobic core at a concentra-
tion 0.01–1 % (w/v) improving DEX sol-
ubility by up to about 10 fold
dh 10–20 nm DEX-loaded mixed micelles after topical application
at the front of the eye efficiently accumulate into tar-
geted retinal tissue providing DEX therapeutic con-




DEX physically entrapped into micelles




2.4-fold increase in bioavailability to a single instil-
lation of DEX-loaded micelle after a fourfold lower





functional anti-apoptotic gene (bcl-xL)
physically entrapped into micelles by
complex formation
dh = 47.6 nm
 = – 1.3 mV
Eye drop of pCMV–bcl-xL–eGFP-loaded micelles re-









DEX dh 19–23 nm Drug loaded micelles provide improved both the
drug permeation across cell-based epithelial models




Plasmids (pCMV-Lac Z, pK12-Lac Z
and pKera3.2-Lac Z) containing the Lac
Z gene physically entrapped into mi-
celles by complex formation
dh 150–200 nm Cornea epithelium- and stroma-specific gene expres-
sion could be achieved using cornea-specific promot-
ers of keratin 12 and keratocan genes, and the gene
was delivered with PM formulation through non-in-
vasive, eye drop in mice and rabbits. The transfection
mechanism of plasmid-PM may involve endocytosis






CsA physically entrapped into micelles
by dialysis method; drug-loading ratio:
6.2%
dh < 230 nm Prolonged residence time of CsA-loaded CS-CH mi-




Ionic dendrimer type porphyrin derivate
physically entrapped into PIC micelles
dh 10–100 nm Improved ocular photodynamic therapy after intrave-
nous application of photosensitive drug-loaded PIC





PLC physically entrapped into micelles
by direct dissolution method; entrapment
efficiency: 1.9%
dh 18.7–30.3 nm Enhanced miotic response to a single instillation of
PLC-loaded micelle formulations in comparison with





TR physically entrapped into micelles at
a concentration 1 % (w/v)
TR-loaded micelle formulation improved bioavaila-
bility to a small but statistically significant extent in





CsA physically entrapped into micelles
at a concentration 0.1 % (w/v)
dh = 200 nm The micelle formulation improves both the CsA
trans-corneal permeation and the CsA distribution




plasmid DNA with lacZ gene physically
entrapped into micelles by complex for-
mation
dh = 155 nm
 = – 4.4 mV
Enhanced gene expression in the iris, sclera, con-
junctiva, and lateral muscle of rabbit eyes and also in





IND physically entrapped into micelles
at a concentration 0.1 % (w/v)
Improved bioavailability and faster onset time of
IND-loaded micelle formulation in comparison







KT physically entrapped into micelles;
entrapment efficiency: 80%
dh  35 nm Corneal penetration of KT from micelles is much
higher compared to aqueous suspension of drug.
The formulation also shows much higher anti-in-
flammatory activity for longer duration compared
to that of aqueous suspension of drug.
32
Poly(hydroxyethylaspartamide) (PHEA); polyethylene glycol (PEG); PEG-b-poly(L-lysine) (PEG-PLL); PEG-b-poly(aspartic acid) (PEG-PAA); hexadecylamine
(C16); methoxy poly(ethylene) glycol-hexylsubstituted poly(lactides) (MPEG-hexPLA) copolymers; D-alpha tocopheryl polyethylene glycol 1000 succinate (vita-
min E TPGS), PEG-40 octyl phenyl ether (Octoxynol-40); cholesterol (CS); chitosan (CH); Tyloxapol® (TY); Cremophor EL (CR); Pluronic® P 85 (P 85);
Pluronic® F 68 (F 68); Pluronic® F 127 (F 127); N-isopropylacrylamide (NIPAAM); vinyl pyrrolidone (VP); acrylic acid (AA); N,N-methylene bis-acrylamide
(MBA); cyclosporine A (CsA); dexamethasone (DEX); indomethacin (IND); pilocarpine (PCL); tropicamide (TR); ketorolac (KT); polyion complex (PIC); hydro-
dynamic diameter (dh); zeta-potential ().
Physicochemical considerations
Polymeric micelles are spontaneously formed
in aqueous media via the self-assembly of amphi-
philic block copolymers into nano-sized particles at
or above the critical micelle concentration (cmc).
During the micellization process, the hydrophobic
blocks associate to form the core region, whereas
the hydrophilic segments form hydrophilic shell of
micelles. Amphiphilic block copolymers can be tai-
lored to have unique properties with respect to de-
livery requirements, such as to prolong the stability
of micelles in the eye fluids, to enhance residence
time at the absorption membrane, and to modify the
drug release profiles. The shell is responsible for
micelle stabilization and in particular circumstances
interactions with absorption membranes. The most
commonly used shell-forming polymer is poly(eth-
ylene oxide) (PEO) or poly(ethylene glycol) (PEG).
PEO has unique solution properties, including mini-
mal interfacial free energy with water, high aqueous
solubility, high mobility, and large exclusion vol-
ume. PEO stabilizes the interface between the bulk
aqueous phase and the hydrophobic core of mi-
celles by steric repulsive inter-particle forces. From
biopharmaceutical viewpoint, PEO has low toxicity
and immunogenicity, minimize protein adsorption
to micelle surfaces and improve the micelles bio-
compatibility.52 The use of other hydrophilic poly-
mers as shell-forming blocks has been reported for
their bioadhesive or thermoresponsive properties.
Biodegradable polyesters such as poly(lactic
acid) (PLA), poly(-caprolactone) (PCL), and
poly(glycolic acid) (PGA) are most commonly used
polymers to encapsulate small lipophilic drugs. Yet,
the polyion-complex (PIC) micelles are formed by
electrostatic interaction of charged polymer blocks,
such as poly(ethyleneimine) (PEI), poly(aspartic
acid) and poly(L-lysine) (PLL), and nucleic
acid-based therapeutics (e.g., plasmid DNA, siRNA)
or oppositely charged protein drugs.
The drugs may be loaded in the micelle core by
chemical, physical, or electrostatic means. How-
ever, the physical procedures of encapsulation are
preferred. Commonly used physical methods in-
clude direct dissolution, dialysis, oil-in-water emul-
sion, various modifications of film-methods, and
complexation. Depending on the method, drug
loading may occur during or after micelle self-as-
sembly.52,53 The dialysis method consists in bring-
ing the active components and copolymer from an
organic water-miscible solvent in which they are
both soluble (e.g. ethanol, dimethylsulfoxide, di-
methylacetamide, tetrahydrofuran) to a solvent that
is selective only for the hydrophilic part of the co-
polymer (i.e. different aqueous based solvent).53
The size and polydispersity as well as the weight
fraction or yield of polymeric micelles obtained
may vary depending on the organic solvent em-
ployed.54 However, to ensure the complete removal
of the organic solvent used, the dialysis has to be
extended over several days, which is quite inappro-
priate for industry. The oil-in-water emulsion method
consists in preparing an aqueous solution of the co-
polymer to which the solution of drug in the wa-
ter-immiscible volatile solvent (e.g. chloroform) is
added in order to prepare an oil in water emulsion
followed by evaporation of volatile solvent.53 This
method should be avoided when preparing the mi-
celles intended for ocular delivery because it is al-
most impossible to completely remove the toxic
chlorinated solvents during the evaporation process.
The film-method was subjected to various modifi-
cations but usually include following steps: the ad-
dition of copolymer and organic drug solution to an
empty vial, the evaporation of organic solvent and
the formation of copolymer/drug matrix film on the
vial walls. The micelles are formed during the
rehydration of the matrix film by the addition of the
aqueous solvent.53,54 This method is suitable for the
preparation of micelle for ocular delivery because
the organic solvent can be practically completely
removed. This method may also result in the signif-
icant increase in the drug loading. Finally, the
drug-loaded micelles can be prepared by the simple
equilibration of the drug and polymeric micelles in
aqueous media. Even though, direct dissolution
method may not result in the high levels of drug
loading, it should be emphasized that this method is
the simplest method of micelle preparation with the
great potential for scale-up through industry. Fur-
thermore, the usage of toxic solvent is avoided in
this method. By the principles of simplicity and
safety, this method should be preferred for the prep-
aration of micelles envisioned for ophthalmic deliv-
ery. Yet, combing the hydrophobic effect between
block copolymers and drugs with other interactions
such as hydrogen bonding, electrostatic interaction
and dipole-dipole interaction should enhance the
drug loading capacity of polymer micelles. PIC mi-
celles, however, are prepared by simple mixing of
aqueous solutions of block copolymer containing
neutral block and ionic block (e.g. PEG-b-poly-
cationic copolymers), and aqueous solution of
pDNA, siRNA or negatively charged proteins.55
The hydrophobic micelle core is formed by electro-
static interaction of polycationic portion of copoly-
mer and oppositely charged biomolecules. Due to
the highly dense hydrophilic shell surrounding the
PIC core, the PIC micelles exhibit excellent stabil-
ity in aqueous media and high tolerability against
nuclease or protease degradation of encapsulated
biomolecules.56 However, further modification of
PIC micelles will be necessary to retain their stabil-
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ity under harsh in vivo conditions in the eye, and to
achieve the delivery of the cargo in the right cellu-
lar space.
The release of drug from polymeric micelles
depends on the rate of diffusion of the drug from
the micelles, micelle stability and the rate of bio-
degradation of the copolymer. If the micelle is sta-
ble and the rate of biodegradation of copolymer is
slow, the release rate will be mostly influenced by
the strength of the interaction between the drug and
the core-forming block.54 The drug release rate is
particularly important for ophthalmic delivery. It is
crucial to establish the right balance between the
drug release rate from the micelles and their drain-
age from the various eye compartments. The drug
release profile should be tailored depending on the
dynamics of eye compartments in which the drug is
applied. More precisely, if the site of drug action is
the tissue associated with aqueous humor and the
drug-loaded polymeric micelles are not absorbed
across cornea after topical drop-wise application,
the drug needs to be released from the micelles and
the free drug needs to be absorbed in the great ex-
tent across the cornea in the process that is faster
than the drug-loaded micelle and/or free drug drain-
age occurs. Contrary, if the drug-loaded polymeric
micelles are applied by injection into vitreous hu-
mor, than there is no danger of washing out of mi-
celles from the site of application because the vitre-
ous humor is very static environment and the re-
lease profile of drugs should be set up to ensure ef-
fective dose of drug during the prolonged period of
time and thus reduce the frequency of invasive ap-
plication.
In the case of PIC micelles, it is of crucial im-
portance that the release of the encapsulated bio-
tech-drugs does not occur before the internalization
of intact micelles because the biotech-drugs cannot
cross the plasma membrane themselves. This points
out the importance of the stability of PIC micelles
in the tears if applied as eye drops and the stability
in the extracellular matrix in ocular tissues if in-
jected intraocularly.
Polymeric micelles usually range in size be-
tween 10 and 100 nm. This range is even smaller
than the size of other new self-assembled delivery
system such as dexamethasone-loaded cubosomes
ranging in sizes from about 214 to about 226 nm.26
The sizes of polymeric micelles are similar to the
sizes of natural nanocarriers such as serum lipo-
proteins and viral particles. Different physicoche-
mical and biopharmaceutical properties of the poly-
meric micelles are related to their size. With respect
to the patient convenience, it is important that the
particle size for ophthalmic applications is within
the nano range because with larger sizes a scratch-
ing feeling of foreign body sensation might occur.
An aqueous-based micelle nanodispersions are sim-
ilar to conventional eye drops because they have
drug-loaded particles in colloidal form in a liquid
vehicle similar to eye drops. These nanodispersions
can be conveniently administered to the ocular sur-
face like aqueous solution but with lower frequency
of dose. The stability of polymeric micelles, both
physical and biological, is closely associated with
their colloidal size range as well as their common
narrow size distributions. Drug loading efficiency
as well as its release profile might be dependent on
size and shape of micelle nanocarriers. The size of
polymeric micelles can largely influence on their
eye biofate. It plays an important role in the ability
of polymeric micelles to interact with eye surfaces,
in particular, with the mucosal epithelia. Further-
more, the size of externally applied micelles could
influence the absorption or permeation through the
ocular barriers. The size plays a crucial role in de-
termining the efficiency of endocytosis, and also in
determining the mechanism of internalization of
nanosystems in the cell (e.g. clathrin mediated or
caveolin-mediated endocytosis).57,58 Moreover, the
size could play a decisive role for the paracellular
transport of polymeric micelles through the hydro-
philic pores of tight junctions.
Besides the size, the surface charge of poly-
meric micelles is also important considering their
physicochemical and biological properties. Poly-
meric micelles can be stabilized either by electro-
static stabilization or by steric stabilization or by a
combination of both. The micelle surface charge
determined by the zeta-potential values allows the
formation of the stable micelle nanodispersion. Fur-
thermore, surface charge of polymeric micelles de-
termines their interactions with eye surfaces and/or
cell membranes. In particular, different types of
electrostatic interactions (e.g. ionic interaction or
hydrogen bonds) with the negatively charged sialic
acid residues of mucin, usually depending on the
environmental pH and/or ionic strength, define
polymeric micelles retention on the absorbing sur-
face. For comparison, positively charged liposomes
seem to be preferentially captured at the negatively
charged corneal surface compared to neutral and
negatively charged liposomes.17
Even though the polymer micelle is the physi-
cally self-assembled dynamic structure, their physi-
cal stability in aqueous solutions is enhanced in
comparison to low-molecular-weight surfactants.
The physical stability of polymeric micelles in-
cludes their thermodynamic and kinetic stability.
The micelles formed from amphiphilic block copol-
ymers are more thermodynamically stable than
those formed from low-molecular-weight surfac-
tants. Increased thermodynamic stability is related
to low cmc values of polymeric micelles allowing
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them to be less prone to disassembly at low concen-
trations than standard surfactants.52,59 For example,
the cmc value of polyoxyethylated nonionic surfac-
tants in general is about two orders of magnitude
lower than the corresponding anionics with the
same alkyl chain length.60 Polymeric micelles also
possess noteworthy kinetic stability, meaning that
the dissociation of polymeric micelle structures into
unimers is a slow process, even when the system is
subjected to dilution below cmc.52,59 Moreover, it is
proposed that loading of water insoluble drugs into
micelle hydrophobic cores can further stabilize
polymer micelles.61 Slow dissociation upon dilution
allows polymeric micelles to retain their integrity
and drug content in eye fluids for some time giving
them a chance to reach the target site before disso-
ciation into unimers. However, the interactions of
polymeric micelles with components of eye fluids
(e.g. proteins, mucin, glycosaminoglycans) and
cells need to be evaluated in terms of micelle stabil-
ity and drug release.
The polymeric micelles in vivo are confronted
with numerous eye fluid components affecting their
stability. The influence of these components should
be discriminated within in vitro stability studies.
Thus far, the in vitro stability of ocular drug deliv-
ery nanosystems including polymeric micelles, and
their efficiency in the delivery of encapsulated
drugs in the ocular tissues was studied in the artifi-
cial eye fluids with relatively simple composition.
The artificial tear fluid (pH 7.4, ionic strength
0.188) commonly contains different salts (i.e. so-
dium chloride, sodium bicarbonate, calcium chlo-
ride) dissolved in water18, while the human tears, in
addition to being aqueous solution of electrolytes,
are rather complex mixture of different proteins
(e.g. lysozyme, lactoferrin, lipocalin, secretory
IgA), lipids, and mucin. The importance of stability
studies in complex media is highlighted by the find-
ing that the PEG-b-PCL micelles are stable in sim-
ple media such as phosphate-buffered saline but
disassembled to varying extents with increasing
chemical complexity of media and addition of se-
rum.62
The design strategies for in vitro micelle stabil-
ity should pay special attention on the physico-
chemical properties, composition and dynamics
of the eye fluids. The tears are isotonic (308
mOsmol/kg), low viscous non-Newtonian pseudo-
plastic fluid (1–10 mPa s) with pH values in range
7.3–7.7.3,63 The tear film is composed primarily of
mucus whose primary component is mucin, a
high-molecular-mass glycoprotein that is negatively
charged at physiological pH. The concentration of
mucin in human tears is 100 g ml–1. Proteins in bi-
ological fluids can compromise the stability of
polymeric micelles by adsorption to the micelle sur-
face leading to their disintegration, and consequent
decrease in the transport across the ocular barriers.
For example, negatively charged mucin may desta-
bilize the PIC micelles by the counter polyelectro-
lyte reaction.
Biopharmaceutical considerations
Drug-loaded polymeric micelles should be
carefully designed in order to deliver the drug at the
site of its action. If the site of drug action is cornea
or conjuctiva, polymeric micelles should be re-
tained at the ocular surface long enough to ensure
sustained drug release as well as more efficient
drug permeation in the front eye surface tissue (Fig-
ure 1, case 1). At the same time, the adsorption of
intact drug-loaded micelles may be hypothesized
providing sustained drug release and prolonged
therapeutic activity in the corneal tissue. When
dealing with the drug whose site of action is aque-
ous humor associated tissues, then the drug-loaded
polymeric micelles must have potential to be ad-
sorbed across the cornea, releasing the drug in
aqueous chamber (Figure 1, case 2). In the case of
the diseases affecting the posterior eye segment,
and in order to evade the invasive ocular injections
thereby improving patient compliance, polymeric
micelles should reach the posterior of the eye most
probably by trans-scleral route around conjunctiva,
through the sclera, choroid and finally retina (Fig-
ure 1, case 3).40 However, after topical application,
polymeric micelles will encounter different chal-
lenges that they have to overcome in order to suc-
cessfully deliver the drug to the site of action.
Since the volume of human tears in the
pre-corneal area is only 7 l, there will be no sig-
nificant dilution of micelle formulation upon the
application. However, the micelles will be exposed
to the dynamic and complex eye environment, and
they can be immediately washed away from the eye
surface. The tear flow is in the range of 0.5 to
2.2 l min–1 and the contact time with the ocular ab-
sorbing surfaces (cornea or conjunctiva) is typically
less than 2 min. The eye surface is covered by a
thin fluid layer, the so-called precorneal tear film
with the thickness of 3–10 m. The human tear film
is composed of three distinct layers: the thin lipid
layer, the aqueous layer and the mucus layer.64,65
The secreted mucin in tears forms a hydrophilic
layer that covers ocular surface and thereby creates
the negative charge of both corneal and
conjunctival surface. In order to prolong the resi-
dence time at the ocular surface, polymeric micelles
should make an intimate contact with the mucus
layer. Pre-ocular retention of polymeric micelles
can be achieved by the presence of the positive
charge in the hydrophilic micelle shell that will en-
370 I. PEPIÆ et al., Polymeric Micelles in Ocular Drug Delivery: Rationale, Strategies …, Chem. Biochem. Eng. Q. 26 (4) 365–377 (2012)
hance the interactions with negatively charged mu-
cins at the corneal surface.66 Coating of polymeric
micelles by mucoadhesive polymers like chitosan
improves bioavailability of the encapsulated drug
either by prolonging the residence time of micelles
at the mucus site due to ionic interaction between
the positively charged amino groups of chitosan
and the negatively charged sialic acid residues in
mucus, or by the strong effect of chitosan as perme-
ation enhancer, or by a combination of both.37
Without bioadhesion and/or permeation enhancer,
the micelles would be eliminated from the pre-cor-
neal site almost as quickly as aqueous solution.
The precorneal tear film serves as permeability
barrier that could discriminate molecules or parti-
cles by surface properties. Namely, molecules or
particles that engage in strong binding interactions
with the mucus hydrogel become trapped in the
hydrogel matrix independent of their size and
thereby the hydrogel matrix modulates their dif-
fusion behaviour (so-called interaction-filtering
mechanism).67 However, the polymeric micelles
must be mobile and flexible enough to interdiffuse
into the mucus and penetrate to a sufficient depth.
Yet, the stability of the micelles on the negatively
charged mucin surfaces can be compromised.
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F i g . 1 – Fate of drug-loaded polymeric micelles after topical ocular application
There are several possible scenarios predicting
the pre-corneal drug fate regarding the polymeric
micelle relaxation time and the process of drug par-
titioning. If the relaxation time of drug-loaded poly-
meric micelles is short and/or the process of drug
partitioning in and out of micelles is fast, than the
free drug is absorbed into the eye and instantly new
free drug is released from micelles according to a
shift in the equilibrium between free drug and drug
in micelle.60 However, this productive absorption
process takes place as long as drug-loaded poly-
meric micelles are close to absorbing surface. Once
the micelles are removed from the productive ab-
sorption area, the non-productive (systemic) ab-
sorption takes place. Thus, the ocular drug absorp-
tion rates from a micelle and a solution system are
comparable if the effects of surfactants on the phys-
ical properties of the delivery systems and the in-
tegrity of ocular epithelium are negligible. In con-
trast, if we are dealing with the drug-loaded poly-
meric micelles having the longer relaxation time
and/or the slower process of drug partitioning in
and out of micelles, it is possible to achieve micelle
depot at the absorbing surface with prolonged drug
release and therapeutic activity. To achieve sus-
tained drug release and prolonged therapeutic activ-
ity, the micelles need to be retained in the pre-ocu-
lar area after topical administration, and the conse-
quent release of the drug from the micelles at an ap-
propriate rate.
Polymeric micelles have potential to increase
drug permeability via transcellular and/or para-
cellular pathway. The effects of amphiphilic copol-
ymers (unimers) on the transcellular permeability
are well established. Unimers dissociated from mi-
celles may perturb the plasma membrane, resulting
in acceleration of drug permeation through cell
membranes.61 More precisely, these copolymers can
be incorporated into the lipid bilayer, forming polar
defects, which change the physical properties of the
cell membranes. When the lipid bilayer is saturated,
mixed micelles begin to form, resulting in the re-
moval of phospholipids from the cell membranes
and hence leading to the increased transcellular per-
meability.60 In addition, intact polymer micelles can
also enter cells possibly by endocytosis68, but the
mechanisms explaining endocytosis of polymer mi-
celles have not been fully clarified. Moreover, the
trans-corneal absorption of particles smaller than
100 nm has been also reported.17
Tight junctions regulate paracellular movement
of hydrophilic drugs across epithelia. The dimen-
sions of the hydrophilic paracellular pores lie be-
tween 3–5 nm, suggesting that solutes with a mo-
lecular radius exceeding 1.5 nm will be excluded
from this uptake route under normal conditions.
Permeation enhancers could improve corneal bar-
rier restrictions. Polycationic polymers such as
chitosan and poly-L-arginine are reported to in-
crease the trans-epithelial absorption by dissocia-
tion of tight junction assemblies, which restrict the
paracellular permeation in ocular epithelia without
producing significant epithelial damage.66 Taking
into account the flexibility of the micelle structure,
as well as permeation enhancer induced opening of
the tight junctions and enlargement of the para-
cellular pore dimensions, it is possible to envision
the transport of intact micelle through the opened
hydrophilic paracellular pores.17
Moreover, the majority of polyoxyethylated
nonionic surfactants are P-glycoprotein (P-gp)
efflux pump inhibitors that can increase drug ab-
sorption, resulting in a higher bioavailability. The
mechanism of P-gp inhibition by polyoxyethylated
nonionic surfactants has not yet been completely
understood. The use of the nonionic surfactant sys-
tems as a means of delivering poorly absorbed
drugs has been recognized as a strategy to over-
come P-gp efflux activity and improve drug effi-
cacy (e.g. dexamethasone, timolol).60
The approaches to improve the in vivo stability
of polymeric micelles include one or combination
of following strategies: stimuli sensitivity, targeting
moiety, and cross-linking strategy. Stimuli-sensitive
polymer micelles can actively respond to environ-
mental signals, provoking changes of their physical
stability. A representative example is the pH-sensi-
tive polymer micelle, which becomes destabilized
and releases drugs depending on the environmental
pH. For example, Gupta et al.32 prepared the poly-
meric micelles of N-isopropylacrylamide copoly-
mer (NIPAAM), vinyl pyrrolidone (VP) and acrylic
acid (AA) having cross-linkage with N,N-methy-
lene bis-acrylamide (MBA) loaded ketorolac. The
temperature and pH dependent release of drug in
aqueous buffer (pH 7.2) from the polymeric mi-
celles at 25°C were 20 and 60% after 2 and 8 h,
respectively. In vitro corneal permeation studies
through excised rabbit cornea indicated two fold in-
creases in ocular availability with no corneal dam-
age compared to an aqueous suspension containing
same amount of drug as in micelles. The formula-
tion showed significant inhibition of lid closure up
to 3 h and PMN migration up to 5 h compared to
the suspension containing non-entrapped drug,
which did not show any significant effect. Corneal
permeation of ketorolac and anti-inflammatory ac-
tivity from nanoparticles were much higher com-
pared to aqueous suspension of drug of equivalent
concentration. This could be attributed to the small
size (< 50 nm) of the polymeric micelles as well as
their mucoadhesiveness. Also, the ligand-conju-
gated polymer micelle (e.g. folate, antibodies,
growth factors, or homing peptides) increased the
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probability of cellular uptake of polymer micelles.
Those micelles are designed for intracellular deliv-
ery of anticancer drugs. However, this approach can
be an important rationale to develop ligand-conju-
gated polymer micelle for ophthalmic delivery be-
cause eye cells and tissues expressed numerous re-
ceptors. Chemically or electrostatically cross-linked
polymer micelles prevent micelle in vivo disintegra-
tion. However, cross-linking between polymer
chains may result in another problem of controlled
drug release owing to the lack of a biodegradation
mechanism.61
Furthermore, the polymer micelle formulations
have potential for injection applications into differ-
ent eye compartments allowing micelles to be con-
fronted with various compositions of the eye fluids
(aqueous or vitreous humor). The hydrogel forming
vitreous humor is diffusion barrier that restricts
drug permeation to the retina. Interaction-filtering
mechanism might also apply to the vitreous humor
hydrogel that molecules have to permeate to reach
the retinal cells. The major components of vitreous
humor are collagens and anionic glycosamino-
glycans including hyaluronic acid, chondroitin sul-
phate and heparan sulphate. The permeability prop-
erties of the vitreous humor are also selective –
some antibiotics can penetrate the vitreous humor
whereas others are blocked. Similarly, the diffusion
of some small dyes is delayed in the hydrogel,
whereas others, although similar in size, are able to
diffuse freely. This suggests that, also in the ocular
hydrogel, interaction-filtering strategies contribute
to the microscopic regulation of diffusion.67 How-
ever, systematic studies on the permeability proper-
ties of the vitreous humor are still lacking.
The understanding of the behaviour of poly-
meric micelles and their fate in real time in the eye
is necessitated. To clarify the biodistribution of
drug-loaded polymer micelles, their structural in-
tegrity and fate in the eye should be visualized.69
The biodistribution data can represent the real loca-
tion of the polymer micelles only during the time
within the polymeric micelles are stabile in vivo. A
novel fluorogenic-based approach to micelle integ-
rity assessment may be useful to monitor the mi-
celle stability and biodistribution in vivo.62
Eye biofate and safety considerations
The unique characteristics and high sensitivity
of the eye tissues impose distinctive safety require-
ments and great restrictions on the selection of the
components that can be used in the topical ocular
preparations. A special consideration should be
given to the ability of the polymeric surfactants to
affect the integrity of epithelial surfaces potentially
causing irritation and inflammatory changes (burn-
ing, stinging, corneal opacity, conjunctival redness
or chemosis, and discharge). Polymeric surfactants
have potential to induce cytotoxic side effects to the
eye which are dependent on the type and chemical
structure of surfactants to which the eye is ex-
posed.60
The surfactants applied to the eye can be ab-
sorbed through the non-productive routes (conjunc-
tiva, nasal mucosa, lacrimal drainage system, phar-
ynx, gastrointestinal tract, skin at the cheek and
lips) and enter the systemic circulation.60 In most
cases, the molecular weight of polymeric micelles
is in the order of 106 g mol–1. Possessing a much
larger molecular weight than that for critical filtra-
tion in the kidney, polymeric micelles can evade re-
nal filtration.52 Although polymeric micelles are
able to persist for several hours after dilution below
the cmc, upon entering the systemic circulation
they will fall apart at some point through biode-
gradation or through simple dilution into unimers.
The tissue distribution of these surfactants is rela-
tively low due to a moderate to high hydrophilicity
and/or possible strong binding with plasma pro-
teins. The dissociated individual surfactant mole-
cules are below the renal molecular weight thresh-
old and will be eliminated mainly by renal excre-
tion with only a small portion removed by the
biliary secretion. Yet, the clearance path of poly-
meric surfactants through the kidneys or by other
means of excretion opens the potential for micelles
that are very stable in plasma to alter the blood dis-
position and pharmacokinetics of biologically ac-
tive compounds which may affect the toxicity pro-
files of the ophthalmic drugs applied topically as
eye drops.60
Drug-loaded polymeric micelles applied topi-
cally if able to permeate into the eye across the cor-
nea would firstly enter the aqueous humor and then
be distributed to the surrounding tissues. The aque-
ous humor in the anterior and the posterior cham-
bers flow in opposite directions and would hinder
the passage of the micelles from the aqueous humor
to the lens and vitreous humor, thus making this un-
favourable pathway for the posterior of the eye. The
absorbed drug and polymeric surfactant in the ante-
rior eye tissues would be mainly eliminated via
aqueous humor turnover and venous blood flow in
the anterior uvea. Yet, topically applied drug-loaded
polymeric micelles have potential to reach the pos-
terior of the eye by the unconventional pathway of
going around the eye, i.e. trans-scleral route around
conjunctiva, through the sclera, choroid and finally
retina. Permeation of micelles through the
trans-scleral route would be enabled by their small
size and hydrophilic surface properties. Polymeric
micelles would probably travel through the hydro-
philic pores of the sclera, which range from about
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30 nm to about 300 nm in size. Moreover, it was
suggested that the hydrophilic chains in the micelle
corona could partially evade wash-out by the
conjunctival/choroidal blood vessels and lympha-
tics allowing the micelles to reach retina.40 The
absorbed drug and polymeric surfactant from the
posterior eye tissues would be eliminated via poste-
rior (choroidal blood flow) or, less likely, via the
anterior route by diffusion through the vitreous to
posterior chamber and elimination via aqueous
turnover and uveal blood flow.7
Polymeric surfactants are known to be safer
than low-molecular-weight surfactants.70 Polymeric
nonionic surfactants are relatively harmless to the
eye in comparison to the cationic, anionic, or
amphoteric counterparts. They are generally less
toxic, less haemolytic, and less irritating to the eye
tissues, and tend to maintain near physiological pH
values when in solution. Polyoxyethylated nonionic
surfactants have found widespread applications in
ophthalmics among the nonionics. Some polyoxy-
ethylated nonionic surfactants have a long history
of being safe in ophthalmic use. Polysorbate 80 was
reported to be non-irritating to the rabbit eye up to a
concentration of 10% and has been used in a number
of marketed eye drop solutions. Tyloxapol and
Pluronics are also used as formulation components
of several commercial topical ocular products and
have proven to be safe for use.60 Pluronic block co-
polymers are practically safe, particularly those
with a high content of PEO. Core-forming blocks
such as polyesters and poly(L-amino acids) undergo
hydrolysis and/or enzymatic degradation in biologi-
cal environment, producing biocompatible mono-
mers allowing renal elimination. Since the body ef-
fectively deals with these monomers, there is very
minimal systemic toxicity associated by using poly-
esters and poly(L-amino acids) for drug delivery.71
For ocular delivery biodegradable polymers are
preferable and in most cases required.
The surface or interfacial tension that poly-
ethoxylated nonionic surfactants produce in the
concentration they form aggregates is usually
higher compared to that of ionics, making the
nonionics less destructive on cell membranes and
thus less irritating and toxic.60 The polyoxyethyla-
ted nonionic surfactants are safe as permeation pro-
moters. Their apparent safety at the tested concen-
trations was confirmed by their inability to increase
the corneal hydration level beyond the normal
value, and by lack of irritant effect in vivo, as evi-
denced by a Draize test.60
Industrial considerations
The major factors that must be taken into ac-
count while formulating aqueous based polymeric
micelle nanodispersion include required drug thera-
peutic concentration, ocular safety and toxicity of
polymeric micelles, compatibility of polymeric mi-
celles with other formulation ingredients as well as
packaging components, the effect of pH and ionic
strength on stability and/or solubility of drug-loaded
micelles, choice of formulation preservative, ocular
formulation comfort and its ease of manufactur-
ing.48 The aqueous based nanodispersions of poly-
meric micelles can be easily manufactured by the
direct dissolution method. After the simple mixing
of the drug and polymeric micelles in aqueous me-
dia and sterilization via sterile filtration, this sterile
micelle nanodispersion may further be mixed with
previously sterilized solutions of additional compo-
nents such as viscosity enhancing, lubricating,
bioadhesive, buffering, tonicity, chelating, antioxi-
dant and preservative agents. Then the batch is
brought to final volume with additional sterile wa-
ter. For comparison, the manufacture of sterile
nanoparticles is more complicated as compared to
polymeric micelles including more and much com-
plicated manufacturing steps (e.g. milling, homoge-
nization, emulsion techniques).
The major benefit associated with nano-sized
dimensions of polymeric micelles is related to their
sterilization processes in pharmaceutical produc-
tions. Polymeric micelles are simply and inexpen-
sively sterilized by filtration using typical steriliza-
tion filters with 0.45 m or 0.22 m pores owing to
a fact that polymeric micelles are essentially free of
micro-sized particles contamination. In contrast,
other typical pharmaceutical nano-sized carrier sys-
tems (e.g., nanoparticles, liposomes) need a re-
moval of contaminated micron-sized particles.70
The stability of ophthalmic dosage forms deter-
mines the shelf life and expiration dating of the
product.48 It has been already explained that poly-
meric micelles possess high structural stability pro-
vided by the entanglement of copolymer chains in
the inner core. Thus, polymeric micelles can be fab-
ricated by simple techniques with better physical
stability in comparison to other nanocarrier sys-
tems.
Among the possible difficulties related with the
stability of ophthalmic formulations containing
polymeric micelles is the oxidative damage of ac-
tive pharmaceutical ingredients due to the presence
of residual level of peroxides in the polymeric sur-
factants used for the micelle preparation and/or the
susceptibility of polymeric surfactant to autoxida-
tion. This problem is highlighted in the formula-
tions containing high excipient-to-drug ratios. Fur-
thermore, nonionic polymeric surfactant can nega-
tively influence on the effectiveness of preserva-
tives present in the formulation. The free preserva-
tive can be depleted below its biological effective
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level due to the interaction with polymeric surfac-
tants. In the development of ophthalmic formula-
tion containing polymeric micelles a careful evalua-
tion of interactions of polymeric surfactants and
other formulation ingredients should therefore be
performed in order to attain required stability of
polymeric micelles, the shelf-life of the formula-
tion, and the performance of the product.
Nonionic polymeric surfactants influence on
physicochemical characteristics of the formulation,
in particular the dynamic surface tension, viscosity
or other rheological behaviour, which needs to be
taken into consideration during the innovative oph-
thalmic product development. For example, it has
been shown that the lower is the dynamic surface
tension of the solution; the lower is the weight of
drops delivered. The change in viscosity or other
rheological properties including yield stress, stor-
age/loss modulus, and thixotropy as a result of ad-
dition of nonionic surfactants to eye drops may not
significantly affect the drop volume/weight within
the usual concentration range of surfactants used.60
Regulatory considerations related to new oph-
thalmic delivery systems are very complex issues
including preclinical and clinical testing and filing
appropriate applications. The differences between
global medical regulatory authorities create an ad-
ditional obstacle for industry aiming to lunch the
innovative ophthalmic products in various world
markets.48
Patient considerations
To treat the diseases of the anterior part of the
eye, drugs are commonly applied in the form of eye
drops to the eye surface. Due to the physiological
and anatomical constraints, only a small fraction of
drug is ocularly adsorbed, and to achieve pharma-
cological effect the high frequency of dosing is re-
quested. Nanodispersion of polymeric micelles in a
suitable ophthalmic vehicle has the advantage of
application in liquid form just like eye drop solu-
tions while maintaining the drug activity at the site
of action. Bioadhesive properties of polymeric mi-
celles minimize the drainage from the ocular sur-
face by interacting with the mucin present in the oc-
ular surface resulting in the enhancement of the
contact time and the increase of the drug bio-
availability. Thus, the frequency of dosing can be
significantly reduced. Moreover, the discomfort as-
sociated with the application of viscous or sticky
preparations that also prolong the residence time on
the eye surface, but lead to a blurring of vision, can
be avoided. The additional advantage of polymeric
micelles is permeation enhancement of the encapsu-
lated drug through ocular barriers. Thus, properly
formulated drug-loaded polymeric micelles may
provide ease of application with lower frequency of
dosing, giving to the ophthalmic products contain-
ing polymeric micelles the advantage of being pa-
tient friendly.
The drug from topically applied drops hardly
reaches the posterior tissues such as choroid and
retina. Thus there is a real problem for the drug to
be efficiently delivered to the posterior segment of
the eye. For the treatment of the diseases affecting
posterior segment of the eye, ophthalmic formula-
tion containing polymeric micelles can be adminis-
tered by two routes, topical and injection 17. Inject-
able route is an invasive method for administration
of therapeutic agents to ocular tissues, however due
to the sustained release of the drug from the poly-
meric micelles, the frequency of injections could be
significantly decreased. The further achievements
in the design of polymeric micelles that may bypass
or transport the drug across various ocular barriers
and sustain its levels at the target site of the eye will
significantly improve ocular drug delivery, and thus
the risk of ocular complications associated with oc-
ular injections could be omitted.40
Concluding remarks
Polymeric micelles have the potential to target
ocular tissues at high therapeutic value offering
several favourable biological properties, such as
biodegradability, biocompatibility and mucoadhe-
siveness, which fulfil the requirements for ophthal-
mic application. Physicochemical characteristics
such as size, surface charge, morphology, physical
state of the encapsulated drug, drug release proper-
ties and stability of the nanosystems are of particu-
lar importance for topical ocular application. Poly-
meric micelles dispersed in aqueous solutions can
be stabilized either by electrostatic stabilization or
by a combination of both. Adequate surface charge
of polymeric micelles can be achieved to produce a
stable colloidal dispersion. Furthermore, surface
charge of topically applied polymeric micelles de-
termines their performance at the absorbing sur-
faces, e.g. their interactions with the cell mem-
branes as well as the glycoproteins of the eye tissue
and/or fluids (e.g. cornea, conjunctiva, tears, vitre-
ous humor) forming a depot with prolonged release
of the loaded drug. Once the drug is released from
the polymeric micelles, drug molecule size, charge,
lipophilicity, solubility in the eye fluid and meta-
bolic stability determine its in vivo fate in the eye
(e.g. trans-corneal, trans-conjunctival/scleral ab-
sorption, metabolic degradation, loss through the
tear drainage). Particle size of topically applied col-
loidal carriers influences absorption or permeation
through the ocular barriers. For example, the nano-
particles of 100 nm are able to permeate across the
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corneal barrier. Surface modification or coating by
biocompatible hydrophilic polymers improves up-
take of polymeric micelles and enhances their sta-
bility.
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